Abstract Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …

Since the emergence of the first case of coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus (SARS-CoV-2), the viral genome has …

Abstract Background Coronavirus disease 2019 (Covid-19) disproportionately results in
hospitalization or death in older patients and those with underlying conditions. Sotrovimab is …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …

The number and variability of the neutralizing epitopes targeted by polyclonal antibodies in
individuals who are SARS-CoV-2 convalescent and vaccinated are key determinants of …

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible
decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and …

Abstract Monoclonal anti‐SARS‐CoV‐2 immunoglobulins represent a treatment option for
COVID‐19. However, their production in mammalian cells is not scalable to meet the global …

Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we …

Abstract B. 1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant most resistant to antibody neutralization. We demonstrate how the dose and number …

ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.
1.526 that is spreading at an alarming rate in the New York City area. Two versions of the …